Cited by 301Schizophrenia research and treatmentTreatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia

Leucht, Stefan, Crippa, Alessio, Siafis, Spyridon, Patel, Maxine X., Orsini, Nicola, Davis, John M.·2020·American Journal of Psychiatry

DOI 10.1176/appi.ajp.2019.19010034

Open this paper in CoChat — free account

Abstract

OBJECTIVE: The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians. The authors sought to fill this gap by conducting dose-response meta-analyses. METHODS: A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms. Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model. The outcome measure was total score reduction from baseline on the Positive and Negative Syndrome Scale or the Brief Psychiatric Rating Scale. The authors identified 95% effective doses, explored whether higher or lower doses than the currently licensed ones might be more appropriate, and derived dose equivalencies from the 95% effective doses. RESULTS: Sixty-eight studies met the inclusion criteria. The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg. For amisulpride and olanzapine, specific data for patients with predominant negative symptoms were available. The authors have made available on their web site a spreadsheet with this method and other updated methods that can be used to estimate dose equivalencies in practice. CONCLUSIONS: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2019.19010034

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. M. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,722
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citation
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citation
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753
Self-citation
The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations
Andreasen, N. C. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291496 · Cited by 1,532
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H. ‐., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K. M., Gerlach, M., Greiner, C., et al. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,494

Show all 100 references

Research works printed but not linked: 12

Belgamwar RB, 2011, Cochrane Database Syst Rev, CD006622
Rattehalli RD, 2016, Cochrane Database Syst Rev, 12, CD006918
Adams CE, 2013, Cochrane Database Syst Rev, CD003082
Li C, 2009, Cochrane Database Syst Rev, CD007474
Donnelly L, 2013, Cochrane Database Syst Rev, CD001951
Higgins JPT, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
Crippa A, 2016, Journal of Statistical Software, Code Snippets, 72, 1
Coppola D, 2011, Psychopharmacol Bull, 44, 54
Cutler AJ, 2010, Psychopharmacol Bull, 43, 37
Lindenmayer JP, 2008, Psychopharmacol Bull, 41, 11
Saha AR, 2002, Int J Neuropsychopharmacol, 5, S185
Samara MT, 2018, Cochrane Database Syst Rev, 5, CD011883

Sorted by citations

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis
Milosavljevic, F., Bukvic, N., Pavlovic, Z., Miljevic, C., Pešic, V., Molden, E., Ingelman-Sundberg, M., Leucht, S., & Jukic, M. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3643 · Cited by 218
Self-citation
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Tandon, R., Nasrallah, H. A., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gäebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.015 · Cited by 205
Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider‐Thoma, J., Davis, J. M., & Leucht, S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02203-y · Cited by 178
Self-citation
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Wu, H., Siafis, S., Hamza, T., Schneider‐Thoma, J., Davis, J. M., Salanti, G., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac001 · Cited by 131
Self-citation
Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117
Self-citation
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Correll, C. U., Solmi, M., Cortese, S., D, M. F. M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 115
Antipsychotic medication for women with schizophrenia spectrum disorders
Brand, B. A., Haveman, Y. R. A., de Beer, F., de Boer, J. N., Dazzan, P., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721004591 · Cited by 106
In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis
Fernández-Abascal, B., Suárez‐Pinilla, P., Cobo-Corrales, C., Crespo‐Facorro, B., & Suárez‐Pinilla, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.005 · Cited by 93
Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia
Leucht, S., Bauer, S., Siafis, S., Hamza, T., Wu, H., Schneider‐Thoma, J., Salanti, G., & Davis, J. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2130 · Cited by 103
Self-citation
The dual hit hypothesis of schizophrenia: Evidence from animal models
Guerrin, C. G. J., Doorduin, J., Sommer, I. E., & de Vries, E. F. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.025 · Cited by 87
Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia
Yoshida, K., & Takeuchi, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113098 · Cited by 84
Brief Psychotic Disorder During the National Lockdown in Italy: An Emerging Clinical Phenomenon of the COVID-19 Pandemic
D’Agostino, A., D’Angelo, S., Giordano, B., Cigognini, A. C., Chirico, M., Redaelli, C., & Gambini, O. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa112 · Cited by 77
Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials
Sabé, M., Zhao, N., Crippa, A., & Kaiser, S. (2021) · Schizophrenia · doi:10.1038/s41537-021-00171-2 · Cited by 74
Self-citation
Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials
Højlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00078-x · Cited by 67
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Kantrowitz, J. T. (2020) · CNS Drugs · doi:10.1007/s40263-020-00752-2 · Cited by 68
Pharmacogenomics in treatment of depression and psychosis: an update
Jukić, M. M., Milosavljević, F., Molden, E., & Ingelman‐Sundberg, M. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.09.011 · Cited by 64
16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro
Sundberg, M., Pinson, H., Smith, R. S., Winden, K. D., Venugopal, P., Tai, D. J. C., Gusella, J. F., Talkowski, M. E., Walsh, C. A., Tegmark, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23113-z · Cited by 57
Identification and treatment of individuals with childhood-onset and early-onset schizophrenia
Correll, C. U., Arango, C., Fagerlund, B., Galderisi, S., Kas, M. J., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.02.005 · Cited by 72
Self-citation
Schizophrenia
Leucht, S., Siafis, S., McGrath, J. J., McGorry, P. D., Howes, O. D., Tamminga, C. A., Carr, R., Bighelli, I., Schneider‐Thoma, J., Priller, J., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00667-6 · Cited by 73
Self-citation
Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy
Okubo, R., Hasegawa, T., Fukuyama, K., Shiroyama, T., & Okada, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623684 · Cited by 53
Tapering antipsychotic treatment
Horowitz, M. A., Murray, R. M., & Taylor, D. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2166 · Cited by 49
Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis
Wu, H., Siafis, S., Wang, D., Burschinski, A., Schneider‐Thoma, J., Priller, J., Davis, J. M., & Leucht, S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.03.015 · Cited by 52
Self-citation
Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis
Wang, D., Schneider-Thoma, J., Siafis, S., Qin, M., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.03.003 · Cited by 44
“We reviewed previous meta-analyses(Huhn et al., 2019; Leucht et al., 2023; Wang et al., 2023), and we conducted update searches of the Cochrane Schizophrenia Group specialized register on June 14, 2021, September 21, 2021, March 6, 2022, and 25 June 2023 (eAppendix 3).”
MethodInfluentialSelf-citation
BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia
Turkmen, B. A., Yazıcı, E., Güzel, D., Suda, M. A., & Yazıcı, A. B. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03578-4 · Cited by 44
Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine
Sehatpour, P., Iosifescu, D. V., Baun, H. M. D., Shope, C. B., Mayer, M., Gangwisch, J. E., Dias, E. C., Sobeih, T. M., Choo, T.-H. J., Wall, M. M., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.01.015 · Cited by 40
Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis
Takeuchi, H., MacKenzie, N. E., Samaroo, D., Agid, O., Remington, G., & Leucht, S. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa063 · Cited by 39
Self-citation
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
Hart, X. M., Gründer, G., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Cumming, P. D., Frajerman, A., Hefner, G., Howes, O. D., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2366235 · Cited by 39
Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis
Schneider‐Thoma, J., Hamza, T., Chalkou, K., Siafis, S., Dong, S., Bighelli, I., Hansen, W., Scheuring, E., Davis, J. M., Priller, J., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00001-x · Cited by 43
Self-citation
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis
Hart, X. M., Hiemke, C., Eichentopf, L., Lense, X. M., Clement, H. W., Conca, A., Faltraco, F., Florio, V., Grüner, J., Havemann‐Reinecke, U., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06233-2 · Cited by 39
Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.040 · Cited by 38
Schizophrenia
Hasan, A., Falkai, P., Lehmann, I., & Gäebel, W. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0412 · Cited by 37
Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation
Fukuyama, K., Motomura, E., & Okada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032070 · Cited by 33
Reductions in synaptic marker SV2A in early-course Schizophrenia
Yoon, J. H., Zhang, Z., Mormino, E. C., Davidzon, G., Minzenberg, M., Ballon, J. S., Kalinowski, A., Hardy, K. V., Naganawa, M., Carson, R. E., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.026 · Cited by 36
Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials
Wang, D., Schneider-Thoma, J., Siafis, S., Burschinski, A., Dong, S., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad089 · Cited by 29
Self-citation
Mitochondrial Reactive Oxygen Species (mROS) Generation and Cancer: Emerging Nanoparticle Therapeutic Approaches
Wang, X., & Xiong, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s510972 · Cited by 28
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis
Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., & Iwata, N. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05472-5 · Cited by 27
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2)
McAdam, M., Baldessarini, R. J., Murphy, A. L., & Gardner, D. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231205688 · Cited by 26
Aberrant striatal coupling with default mode and central executive network relates to self-reported avolition and anhedonia in schizophrenia
Brakowski, J., Manoliu, A., Homan, P., Bosch, O. G., Herdener, M., Seifritz, E., Kaiser, S., & Kirschner, M. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.047 · Cited by 29
Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
Hart, X. M., Schmitz, C. N., & Gründer, G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.832209 · Cited by 26
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
Miura, I., Horikoshi, S., Ichinose, M., Suzuki, Y., & Watanabe, K. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s366769 · Cited by 26
Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed
Gangadin, S. S., de Beer, F., Wijnen, B. F. M., Begemann, M., van Beveren, N. J. M., Boonstra, N., de Haan, L., Kikkert, M., Koops, S., van Os, J., et al. (2025) · World Psychiatry · doi:10.1002/wps.21315 · Cited by 24
Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials
Osugo, M., Whitehurst, T., Shatalina, E., Townsend, L., O’Brien, O., Mak, T. L. A., McCutcheon, R. A., & Howes, O. D. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104568 · Cited by 24
Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
Osugo, M., Wall, M. B., Selvaggi, P., Zahid, U., Finelli, V., Chapman, G. E., Whitehurst, T., Onwordi, E. C., Statton, B. K., McCutcheon, R. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56663-7 · Cited by 22
Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta‐analysis from two nationwide cohorts
Tiihonen, J., Tanskanen, A. J., Mittendorfer‐Rutz, E., Howes, O. D., Correll, C. U., Siskind, D. J., & Taipale, H. T. (2025) · World Psychiatry · doi:10.1002/wps.21316 · Cited by 23
Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice
Fiorillo, A., Cuomo, A., Sampogna, G., Albert, U., Calò, P., Cerveri, G., Filippis, S. D., Masi, G., Pompili, M., Serafini, G., et al. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2141568 · Cited by 22
Measuring catatonia motor behavior with objective instrumentation
von Känel, S., Nadesalingam, N., Alexaki, D., Gama, D. B., Kyrou, A., Lefebvre, S., & Walther, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.880747 · Cited by 21
Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach
Brodeur, S., Vanasse, A., Courteau, J., Courteau, M., Stip, É., Fleury, M., LESAGE, A. D., Demers, M., & Roy, M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13411 · Cited by 23
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
Srisurapanont, M., Suttajit, S., Likhitsathian, S., Maneeton, B., & Maneeton, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-84836-z · Cited by 21
Identification of clinical phenotypes in schizophrenia: the role of lurasidone
Riva, M. A., Albert, U., Filippis, S. D., Vita, A., & Berardis, D. D. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211012250 · Cited by 20
Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision
Zhang, T., Raballo, A., Zeng, J., Gan, R., Wu, G., Wei, Y., Xu, L., Tang, X., Hu, Y., Tang, Y., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00254-8 · Cited by 18
Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
Leucht, S., & Davis, J. M. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01378-1 · Cited by 18
Self-citation
A pilot study to investigate the efficacy and tolerability of lesion network guided transcranial electrical stimulation in outpatients with psychosis spectrum illness
Raymond, N., Reinhart, R. M. G., Trotti, R. L., Parker, D., Grover, S., Turkozer, B., Sabatinelli, D., Hegde, R. R., Bannai, D., Hoang, D. T., et al. (2023) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2023.103750 · Cited by 20
Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial
Zhao, G., Sun, Y., Zhang, Y., Lu, T., Lu, Z., Kang, Z., Schneider‐Thoma, J., Xie, W., Yang, Y., Guo, J., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250111 · Cited by 16
Self-citation
Antipsychotic dopamine D2 affinity and negative symptoms in remitted first episode psychosis patients
de Beer, F., Wijnen, B. F. M., Wouda, L., Koops, S., Gangadin, S. S., Veling, W., van Beveren, N. J. M., de Haan, L., Begemann, M., & Sommer, I. E. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.09.030 · Cited by 15
Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis
Tian, J., Siafis, S., Lin, X., Wu, H., Schneider‐Thoma, J., & Leucht, S. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.02.012 · Cited by 15
Self-citation
Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis
Samara, M. T., Lappas, A. S., Pinioti, E., Glarou, E., Fober, I., Christogiannis, C., Siafis, S., Christodoulou, G. N., Helfer, B., Mavridis, D., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103291 · Cited by 17
Self-citation
Increased ventral striatal functional connectivity in patients with schizophrenia during reward anticipation
Carruzzo, F., Kaiser, S., Tobler, P. N., Kirschner, M., & Simon, J. J. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102944 · Cited by 15
Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose–response meta-analysis
Lin, Y., Chen, Y. B., Hung, K., Liang, C., Tseng, P., Carvalho, A. F., Vieta, E., Solmi, M., Lai, E. C., Lin, P., et al. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2024-301165 · Cited by 16
Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000–2019: 20-year investigation of who receives treatment, with which agents and at what doses
Richards‐Belle, A., Launders, N., Hardoon, S. L., Man, K. K. C., Bramon, E., Osborn, D., & Hayes, J. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.186 · Cited by 15
Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review
Fagiolini, A. M., Cuomo, A., Berardis, D. D., Dell’Osso, B. M., Pompili, M., & Serafini, G. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000578 · Cited by 14
Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
Miron, A. A., Petric, P. S., Teodorescu, A., Ifteni, P. I., Chele, G. E., & Szalontay, A. S. (2023) · Brain Sciences · doi:10.3390/brainsci13020173 · Cited by 13
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia
Yu, C., Carvalho, A. F., Thompson, T., Tsai, T., Tseng, P., Hsu, C., Hsu, T., & Liang, C. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2022-300546 · Cited by 13
Effect of quetiapine on inflammation and immunity: a systematic review
Ferrari, M., Godio, M., Martini, S., Callegari, C., Cosentino, M., & Marino, F. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2101928 · Cited by 15
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review
Gannon, L., Reynolds, J., Mahon, M., Gaughran, F., & Lally, J. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231168788 · Cited by 13
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198463 · Cited by 12
Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
Correll, C. U., Fusar‐Poli, P., Leucht, S., Karow, A., Marić, N. P., Moreno, C., Nordentoft, M., & Raballo, A. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s345066 · Cited by 13
Self-citation
Multimodal Neuroimaging Summary Scores as Neurobiological Markers of Psychosis
Rodrigue, A., Hayes, R. A., Waite, E., Corcoran, M., Glahn, D. C., & Jalbrzikowski, M. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad149 · Cited by 12
Abnormal circadian rhythm of heart rate variability and their association with symptoms in patients with major depressive disorder
Li, B., Guo, S., Xu, H. Y., Zhou, Y., Zhang, M., Wang, J., Chen, Y., Chen, H., Song, J., & Tan, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.102 · Cited by 12
Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials
Yang, X. S., Fang, S., Lyu, W., Hu, Y., Xu, H., Jiang, X., Zhao, Y., Zhang, Y., Li, J., & Kuang, W. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13709 · Cited by 12
Antipsychotics and Risks of Cardiovascular and Cerebrovascular Diseases and Mortality in Dwelling Community Older Adults
Perreault, S., Boivin‐Proulx, L., Brouillette, J., Jarry, S., & Dorais, M. (2024) · Pharmaceuticals · doi:10.3390/ph17020178 · Cited by 11
High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
Reynolds, G. P. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026456 · Cited by 13
Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial
Gómez‐Revuelta, M., Pelayo‐Terán, J. M., Vázquez-Bourgón, J., de la Foz, V. O., Son, J. M.-V., Ayesa‐Arriola, R., & Crespo‐Facorro, B. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.009 · Cited by 10
Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study
Köck, P., Lang, E., Trulley, V.-N., Dechent, F., Mercer‐Chalmers‐Bender, K., Frei, P., Huber, C. G., & Borgwardt, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.736822 · Cited by 9
Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer’s disease: A systematic review and network meta-analysis
Terao, I., & Kodama, W. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251340901 · Cited by 9
Factors predicting high-dose and combined antipsychotic prescribing in New Zealand
Burness, C. B., Corbet, C., Beyene, K. A., Webby, C., Nankivell, C., Cabasag, P., Hari, K., Fraser, A., Gray, S., Harrison, J., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113996 · Cited by 9
Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real‐World Observational Study
Brodeur, S., Vanasse, A., Courteau, J., Stip, É., LESAGE, A. D., Fleury, M., Courteau, M., & Roy, M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13413 · Cited by 11
Enhanced L-β-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine
Fukuyama, K., Motomura, E., & Okada, M. (2023) · Biomolecules · doi:10.3390/biom13050862 · Cited by 9
Involvement of the TRPV1 receptor and the endocannabinoid system in schizophrenia
Huang, J., Huang, H., Liu, M., Yang, W., & Wang, H. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111007 · Cited by 9
Real-World Treatment of Schizophrenia in Adults With a 22q11.2 Microdeletion: Traitement dans le monde réel de la schizophrénie chez des adultes atteints du syndrome de microdélétion 22q11.2
Van, L., Heung, T., Reyes, N. G. D., Boot, E., Chow, E. W. C., Corral, M. R., & Bassett, A. S. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241293983 · Cited by 10
Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood
Verdolini, N., Borràs, R., Sparacino, G., Garriga, M., Sagué‐Vilavella, M., Madero, S., Palacios‐Garrán, R., Serra‐Navarro, M., Forte, M. F., Salagre, E., et al. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13415 · Cited by 8
Comparison of Aripiprazole and Risperidone effectiveness in treating obsessive‐compulsive disorder in patients with bipolar disorder: Double‐blind, randomized clinical trial
Khorshidian, F., Hamidia, A., Kheirkhah, F., Moghadamnia, A. A., Bijani, A., Mirtabar, S. M., & Koutanaei, S. J. (2023) · Health Science Reports · doi:10.1002/hsr2.1531 · Cited by 7
Helping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 9
Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review
Laguado, S. A., & Saklad, S. R. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.08.254 · Cited by 9
The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment
Schoretsanitis, G., Correll, C. U., Agorastos, A., Compaired, A., Erzın, G., Grigoras, R. M., Benussi, M. G., Gondek, T. M., Gülöksüz, S., Højlund, M., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2367138 · Cited by 8
Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
Kishi, T., Nosaka, T., Sakuma, K., Okuya, M., & Iwata, N. (2020) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12131 · Cited by 8
Altered functional connectivity in psychotic disorder not otherwise specified
Kim, W., Heo, D.-W., Shen, J., Tsogt, U., Odkhuu, S., Lee, J., Kang, E., Kim, S., Suk, H., & Chung, Y. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114871 · Cited by 8
Theta-Burst Stimulation for Auditory-Verbal Hallucination in Very-Late-Onset Schizophrenia-Like Psychosis—A Functional Magnetic Resonance Imaging Case Study
Zöllner, R., Hübener, A.-F., Dannlowski, U., Kircher, T. T. J., Sommer, J. B., & Zavorotnyy, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00294 · Cited by 9
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241272790 · Cited by 7
Antipsychotic prescribing practices and their association with rehospitalization in a forensic psychiatric sample
Goody, J., Petersen, K. L., Brink, J., Crocker, A. G., & Nicholls, T. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1474626 · Cited by 7
Prior Expectations of Volatility Following Psychotherapy for Delusions
Sheffield, J. M., Sloan, A. F., Corlett, P. R., Rogers, B. P., Vandekar, S., Liu, J., Beals, K., Hall, L. M., Gautier, T., Moussa‐Tooks, A. B., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17132 · Cited by 7
Dopamine D 2/3 R availability after discontinuation of antipsychotic treatment: a [ 11 C]raclopride PET study in remitted first-episode psychosis patients
de Beer, F., de Vries, E. F. J., Wijnen, B. F. M., Begemann, M., van Beveren, N. J. M., Boonstra, N., Gangadin, S. S., de Haan, L., Hamers, I. M. H., Veling, W., et al. (2025) · Psychological Medicine · doi:10.1017/s003329172510161x · Cited by 7
Modeling the Double Peak Phenomenon in Drug Absorption Kinetics: The Case of Amisulpride
Kousovista, R., Karali, G., & Karalis, V. D. (2023) · BioMedInformatics · doi:10.3390/biomedinformatics3010013 · Cited by 8
The development of paliperidone nanocrystals for the treatment of schizophrenia
Lhaglham, P., Jiramonai, L., Liang, X.-J., Liu, B.-C., & Li, F.-Z. (2024) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ad8fe7 · Cited by 5
Divergence of dose–response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study
Takekita, Y., Hiraoka, S., Iwama, Y., Sunada, N., Aoki, N., Ogata, H., Funatsuki, T., Takano, C., Yanagida, T., Koshikawa, Y., et al. (2021) · CNS Spectrums · doi:10.1017/s1092852921000043 · Cited by 7
The Rollercoaster of Paclitaxel in the Lower Limbs and Skeletons in the Closet: An Opinion Review
Katsanos, K. H., Kitrou, P. M., & Spiliοpoulos, S. (2021) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2021.03.537 · Cited by 7
Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
Correll, C. U., Fusar‐Poli, P., Leucht, S., Karow, A., Marić, N. P., Moreno, C., Nordentoft, M., & Raballo, A. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 7
Self-citation
Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
Müller, H., & Moeller, S. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s303817 · Cited by 7

Authors: Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M.
Affiliations: Johns Hopkins University (US)
ORCID: Leucht, Stefan
Crippa, Alessio
Siafis, Spyridon
Patel, Maxine X.
Orsini, Nicola
Davis, John M.
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2020-04-01
Volume: 177
Issue: 4
Pages: 342-353
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.2019.19010034
OpenAlex: W2995680584
Cited by: 301
References: 100
Citations by year: 2026: 37 · 2025: 64 · 2024: 63 · 2023: 37 · 2022: 38 · 2021: 46 · 2020: 16
FWCI: 4.20
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: Sanofi
Teva Pharmaceutical Industries
Sunovion
National Institute for Health and Care Research (NIHR/CS/009/010)
Gedeon Richter
H. Lundbeck A/S
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: dose-response relationship, antipsychotic drugs, acute schizophrenia, atypical antipsychotics, haloperidol, long-acting injectable antipsychotics, positive symptoms, negative symptoms, Brief Psychiatric Rating Scale, risperidone, olanzapine, aripiprazole, amisulpride
MeSH terms: Aripiprazole, Paliperidone Palmitate, Lurasidone Hydrochloride, Quetiapine Fumarate, Olanzapine, Acute Disease, Administration, Oral, Clozapine, Delayed-Action Preparations, Dose-Response Relationship, Drug, Haloperidol, Humans, Imidazoles, Indoles, Isoxazoles, Piperazines, Piperidines, Schizophrenia, Schizophrenic Psychology, Thiazoles, Thiophenes, Antipsychotic Agents, Quinolones, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks